Product Description
Mechanisms of Action: mAChR Agonist, nAChR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Belgium | Brazil | Canada | Chile | Colombia | Czech | Dominican Republic | Ecuador | France | Germany | Hong Kong | Hungary | Ireland | Korea | Lebanon | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Singapore | Slovenia | Sweden | Switzerland | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: T.C. ORDU ÜNİVERSİTESİ
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Presbyopia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20244219 |
CTR20244219 | P2 |
Recruiting |
Presbyopia |
None |
2025-06-29 |
Patient Enrollment|Treatments |
Recent News Events
Date |
Type |
Title |
|---|